Obesity and chemotherapy administration: between empiric and mathematic method review

References

• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet Lond Engl. 2008;371:569–578.
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647–1654.
   PubMed Web of Science ®Google Scholar
• Lashinger LM, Rossi EL, Hursting SD. Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation. Clin Pharmacol Ther. 2014;96:458–463.
   PubMed Web of Science ®Google Scholar
• Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45–52.
   PubMed Web of Science ®Google Scholar
• Cleary MP, Grossmann. Minireview ME. Obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150:2537–2542.
   PubMed Web of Science ®Google Scholar
• Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol. 1984;18:941–946.
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol. 2015;138:201–206.
   PubMed Web of Science ®Google Scholar
• Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303–311. discussion 312–313.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Watanabe T, Sakamoto A, et al. Studies on the physical surface area of Japanese. 18. Calculation formulas in three stages over all ages]. Jpn J Hyg. 1968;23:443–450. [
   PubMedGoogle Scholar
• Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970;54:225–235.
   PubMedGoogle Scholar
• Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62–66.
   PubMed Web of Science ®Google Scholar
• Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab. 2001;281:E586–E591.
   PubMed Web of Science ®Google Scholar
• Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
   PubMed Web of Science ®Google Scholar
• Shuter B, Aslani A. Body surface area: Du Bois and Du Bois revisited. Eur J Appl Physiol. 2000;82:250–254.
   PubMed Web of Science ®Google Scholar
• Yu C-Y, Lo Y-H, Chiou W-K. The 3D scanner for measuring body surface area: a simplified calculation in the Chinese adult. Appl Ergon. 2003;34:273–278.
   PubMed Web of Science ®Google Scholar
• Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34:1066–1069.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. American Society of Clinical Oncology, appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. JCO. 2012;30:1553–1561.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267–1273.
   PubMed Web of Science ®Google Scholar
• Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. JCO. 1996;14:3000–3008.
   PubMed Web of Science ®Google Scholar
• Furlanetto J, Eiermann W, Marmé F, et al. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. Ann Oncol. 2016;27:2053–2059.
   PubMed Web of Science ®Google Scholar
• Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J Natl Cancer Inst. 1998;90:1205–1211.
   PubMed Web of Science ®Google Scholar
• Lote H, Sharp A, Redana S, et al. Febrile neutropenia rates according to body mass index and dose capping in women receiving chemotherapy for early breast cancer. Clin Oncol R Coll Radiol G B. 2016;28:597–603.
   PubMed Web of Science ®Google Scholar
• Carroll JP, Protani MM, Nguyen L, et al. Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Med Oncol Northwood Lond Engl. 2014;31:881.
   PubMed Web of Science ®Google Scholar
• Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer. 2007;43:544–548.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Li S, Gelber RD, International Breast Cancer Study Group, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet Lond. Engl. 2005;366:1108–1110.
   PubMed Web of Science ®Google Scholar
• Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 2001;40:67–71.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Stocker G, Hacker UT, Fiteni F, et al. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. Eur J Cancer Oxf Engl 2018;99:49–57.
   PubMed Web of Science ®Google Scholar
• Chambers P, Daniels SH, Thompson LC, et al. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2012;23:748–753.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from intergroup trial 0114. JCO. 2004;22:648–657.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–495.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. Gynecol Oncol. 2009;114:53–56.
   PubMed Web of Science ®Google Scholar
• Au-Yeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014;133:16–22.
   PubMed Web of Science ®Google Scholar
• Hansen J, Stephan J-M, Freesmeier M, et al. The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients. Gynecol Oncol. 2015;138:154–158.
   PubMed Web of Science ®Google Scholar
• Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:353–358.
   PubMed Web of Science ®Google Scholar
• Barrett SV, Paul J, Hay A, Scottish Gynaecological Cancer Trials Group, et al. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol Off J Eur Soc Med Oncol. 2008;19:898–902.,
   PubMed Web of Science ®Google Scholar
• Georgiadis MS, Steinberg SM, Hankins LA, et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst. 1995;87:361–366.
   PubMed Web of Science ®Google Scholar
• Wu W, Liu X, Chaftari P, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS One. 2015;10:e0122047.
   PubMed Web of Science ®Google Scholar
• Gay C, Delarue R, Milpied N, et al. Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. Blood. 2017;129:2811–2813.
   PubMed Web of Science ®Google Scholar
• Cahu X, Carré M, Recher C, et al. Impact of body-surface area on patients’ outcome in younger adults with acute myeloid leukemia. Eur J Haematol. 2017;98:443–449.
   PubMed Web of Science ®Google Scholar
• Kempf E, Hirsch P, Labopin M, et al. Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. Leuk Res. 2014;38:1425–1429.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Wang T, Pérez WS, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17:1765–1774.
   PubMed Web of Science ®Google Scholar
• Lopes-Serrao MD, Ussery SMG, Hall RG, et al. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. JOP. 2011;7:13–17.
   PubMedGoogle Scholar
• Abdah-Bortnyak R, Tsalic M, Haim N. Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability. Med Oncol. 2003;20:363–368.
   PubMed Web of Science ®Google Scholar
• Hourdequin KC, Schpero WL, McKenna DR, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:2952–2962.
   PubMed Web of Science ®Google Scholar
• Lee D, Shook RP, Drenowatz C, et al. Physical activity and sarcopenic obesity: definition, assessment, prevalence and mechanism. Future Sci OA 2016;2. doi:10.4155/fsoa-2016-0028.
   Web of Science ®Google Scholar
• Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:ii1–ii9.
   PubMed Web of Science ®Google Scholar
• Anandavadivelan P, Brismar TB, Nilsson M, et al. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin. Nutr Edinb Scotl. 2016;35:724–730.
   PubMed Web of Science ®Google Scholar